Epidermolysis Bullosa clinical trials

Explore recruiting epidermolysis bullosa clinical trials.

Recruiting epidermolysis bullosa studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Epidermolysis Bullosa trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Safety and efficacy of allogenic adipose tissue-derived mesenchymal stromal cells in patients with epidermolysis bullosa: Clinical trial phase I/II

Czechia

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in Patients with Epidermolysis Bullosa

Italy, Spain, France, Greece, Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

EBUL0. A 20-Week Multicentre, Open Study Assessing the Efficacy and Safety of Apremilast in Patients > 6 years of age with Epidermolysis bullosa simplex generalized

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Exploratory evaluation of the effect of cholestyramine on serum levels of persistent organic pollutants in obese patients

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase I/II ex vivo gene therapy clinical trial for RDEB using autologous skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector

France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study with Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) [EBShield Study]

Austria, Poland, Italy, Belgium, France, Ireland +2 more

Phase II and Phase III (Integrated) EU CTIS Study details

Epidermolysis Bullosa trials by city

Epidermolysis Bullosa in Toronto Epidermolysis Bullosa in Vancouver Epidermolysis Bullosa in Montreal Epidermolysis Bullosa in Calgary Epidermolysis Bullosa in Edmonton Epidermolysis Bullosa in Ottawa Epidermolysis Bullosa in Winnipeg Epidermolysis Bullosa in Quebec City Epidermolysis Bullosa in Hamilton Epidermolysis Bullosa in Kitchener Epidermolysis Bullosa in London Epidermolysis Bullosa in Halifax Epidermolysis Bullosa in New York Epidermolysis Bullosa in Los Angeles Epidermolysis Bullosa in Chicago Epidermolysis Bullosa in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease